Abstract
Background and aims
Thiopurine-induced acute pancreatitis (TIP) is one of the most common adverse events among inflammatory bowel disease patients treated with azathioprine (AZA), representing a significant clinical burden. Previous studies focused on immune-mediated processes, however, the exact pathomechanism of TIP is essentially unclear.
Methods
To model TIP in vivo, we triggered cerulein-induced experimental pancreatitis in mice receiving a daily oral dose of 1.5 mg/kg AZA. Also, freshly isolated mouse pancreatic cells were exposed to AZA ex vivo, and acinar cell viability, ductal and acinar Ca2+ signaling, ductal Cl– and HCO3– secretion, as well as cystic fibrosis transmembrane conductance regulator (CFTR) expression were assessed using microscopy techniques. Ras-related C3 botulinum toxin substrate (RAC1) activity was measured with a G-LISA assay. Super-resolution microscopy was used to determine protein colocalization.
Results
We demonstrated that AZA treatment increases tissue damage in the early phase of cerulein-induced pancreatitis in vivo. Also, both per os and ex vivo AZA exposure impaired pancreatic fluid and ductal HCO3– and Cl– secretion, but did not affect acinar cells. Furthermore, ex vivo AZA exposure also inhibited RAC1 activity in ductal cells leading to decreased co-localization of CFTR and the anchor protein ezrin, resulting in impaired plasma membrane localization of CFTR.
Conclusions
AZA impaired the ductal HCO3– and Cl– secretion through the inhibition of RAC1 activity leading to diminished ezrin-CFTR interaction and disturbed apical plasma membrane expression of CFTR. We report a novel direct toxic effect of AZA on pancreatic ductal cells and suggest that the restoration of ductal function might help to prevent TIP in the future.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Acute pancreatitis (AP) is one of the most frequent causes of hospitalization among non-malignant gastrointestinal diseases [1], moreover, the mortality of severe AP may be as high as 25 percent [2]. In adults, the most common etiologies are biliary and ethanol-induced AP, whereas drug-induced AP (DIAP) is regarded as a rare and mild entity accounting for ~ 2–5% of AP episodes [3]. In contrast, DIAP is the leading risk factor for the first attack of AP in children [4]. Although DIAP is generally considered a mild disease, a recent study highlighted that patients with DIAP have a more severe disease course compared with AP of other etiologies [5], which may be explained by the preexisting pathologies and primary disease of DIAP patients. Even more importantly, the treatment of the primary disease usually has to be suspended or delayed due to DIAP, which can lead to relapses or an accelerated disease progression, thus prevention of DIAP is a major unmet need. A better understanding of the pathogenesis of DIAP, which presumably differs among different drugs, may help to overcome this severe side effect. As an example, Peng et al. recently described the pathomechanism responsible for asparaginase-induced AP, which opened preventive opportunities [6]. Asparaginase is an essential treatment for acute lymphoblastic leukemia – the most common malignant disease in children – with AP as a common adverse event occurring in about 5–10% of cases, which is the most frequent cause of discontinuing the asparaginase treatment [7]. Peng et al. demonstrated that similarly to other pancreatitis-inducing agents, the effect of asparaginase involves protease-activated receptor 2, evokes intracellular Ca2+ release followed by Ca2+ entry, and a reduction of Ca2+ extrusion due to decreased intracellular adenosine triphosphate levels, ultimately leading to extensive acinar cell necrosis [6]. In a follow-up manuscript, the authors also proved that galactose administration protects pancreatic acinar cells ex vivo and reduces the severity of AP in vivo, suggesting that galactose would be a valuable addition to the current asparaginase treatment protocol [8].
Another common form of DIAP is thiopurine-induced pancreatitis (TIP), which is one of the most frequent adverse drug reactions observed in patients with inflammatory bowel diseases (IBD) receiving azathioprine (AZA). TIP occurs in up to 8% of the cases [9,10,11,12], whereas AZA treatment increases the risk of AP fivefold compared to no treatment [13, 14]. Moreover, TIP requires the cessation of thiopurine therapy and the change of medication, often to a less effective drug [15], and might be associated with a higher risk of surgery [16]. After their development in the 1950s, the three thiopurines – AZA, 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG) – became the cornerstones of treatment in organ transplantation, and a wide range of inflammatory, autoimmune, and hematological diseases, but the most experience has been gathered in the field of gastroenterology and the management of IBD [17, 18]. Thiopurines express their immunosuppressant effects through their active metabolites, 6-thioguanine-nucleotides, which can incorporate into the DNA and RNA [10], and inhibit the small GTPase, Ras-related C3 botulinum toxin substrate 1 (RAC1), triggering apoptosis [19, 20]. This effect is more pronounced in the rapidly dividing lymphocytes, hence the immunosuppressive effect; however, thiopurines have a quite narrow therapeutic window and their administration induces various adverse events up to a cumulative incidence of 26% [11]. As the pathomechanism leading to the development of TIP is currently not understood, preventive strategies cannot be developed.
Therefore in the current study, our aim was to understand the pathomechanism leading to the development of TIP. Here, we successfully recapitulated TIP in mice and demonstrated that AZA-treated animals are more susceptible to developing AP upon cerulein treatment. When assessing the possible mechanism of TIP, we found that AZA disturbs pancreatic ductal ion and fluid secretion in mouse pancreatic ductal epithelial cells (PDEC), but has no effect on pancreatic acinar cells. Notably, impaired pancreatic ductal secretion was shown previously to increase the severity of AP [21, 22], and we demonstrated that AZA inhibits the ductal Cl–, HCO3–, and fluid secretion in mouse pancreatic ductal cells both in the in vivo and ex vivo models. Importantly, this inhibition was due to an AZA-mediated suppression of RAC1 activity in mouse pancreatic cells leading to decreased co-localization of cystic fibrosis transmembrane conductance regulator (CFTR) and the anchor protein ezrin and impaired plasma membrane localization of CFTR. To our knowledge, this is the first study providing a detailed mechanistic understanding of TIP. Moreover, we argue that stimulation of pancreatic ductal secretion may help to reduce the risk of TIP in IBD patients.
Materials and methods
All used materials with catalog numbers can be found in Tables 1 and 2.
Ethics
All experiments were performed in compliance with the Hungarian regulations and EU directive 2010/63/EU for the protection of animals used for scientific purposes and the study was approved by the National Scientific Ethical Committee on Animal Experimentation (approval nr: CS/I01/2233-4/2018).
Animals
The C57BL6 mice used in this study were 8–12 weeks old and weighed 20–25 g. The gender ratio was 1:1 for all groups. Animals were allowed to have free access to chow and water, kept at a constant 24 °C room temperature and humidity, and under a 12-h light–dark cycle. Animals received VRF1(P) standard rodent food (Special Diets Services, UK, Cat.No.: 801900), and standard bedding (JRS, Germany; REHOFIX MK2000 corn cob) purchased from Akronom, Hungary.
In vivo experimental pancreatitis
Moderate experimental pancreatitis was induced with 8 × 50 μg/body weight in kilograms (kgbw) IP cerulein (Tocris Bioscience, UK) injections administered hourly, as described previously [22, 23]. Sham control animals received intraperitoneal (IP) physiologic saline injections. Mice were sacrificed one or four hours after the last injection unless otherwise stated, then pancreata were removed, washed with physiologic saline, cleaned from lymph nodes and fat, and stored at + 4 °C in 4% formaldehyde. Paraffin-embedded sections of the pancreas were stained with hematoxylin–eosin following standard protocol. During the histologic evaluation, the severity of pancreatitis was assessed independently by three observers, blinded for the experimental setup, based on the histologic scores of 3 random fields per slide. The extent of the tissue edema, and leukocyte infiltration, were scored from 0 to 5 and the proportion of acinar cell necrosis was evaluated as previously described [21]. Images were captured with a Zeiss AxioImager.M2 with 5× objective (N-Achroplan 5x/0.15 M27; Zeiss, Germany). To determine the serum amylase activity, blood samples were collected into tubes containing no anticoagulants by cardiac puncture under ketamine-xylazine anesthesia. Within an hour after collection, blood samples were centrifuged at 2000 × g for 20 min at 4ºC, then stored at -20 °C until activity measurements or used immediately. To determine the serum alpha-amylase activity, a 4,6-ethylidene(G1)-4-nitrophenyl(G7)-a-(1–4)-D-maltoheptaoside (EPS)-based kinetic assay was used following the manufacturer’s protocol (Diagnosticum Zrt, Hungary, see Table 1.). Briefly, 20 µL serum sample was diluted and from the diluted sample 4 µL was pipetted onto a 96-well plate, then samples were incubated at 36 °C with the alpha-glucosidase containing reagent for 3 min and the reaction was started with the application of the EPS substrate solution; the sample-reagent ratio was 1:75, the enzyme–substrate ratio was 5:1. After 3 min shaking of the plates, the absorbance (A) of the wells was measured at 410/505 nm for 20 min with a CLARIOStar plate reader (BMG Labtech, Germany), and the slope of absorbance (∆A/min) was determined for each well using blank corrected values in the MARS Software (BMG Labtech, Germany). Amylase activity was calculated according to the equation given by the assay manufacturer (7280 × ∆A/min = 1 IU/ml) and standardized to body weight and serum protein content. Before the measurements, the optimal dilution of samples was determined to ensure that the amylase activity was within the linear range of the assay.
Per os treatment of mice with thiopurines
Based on previous pharmacokinetic studies, the usual therapeutic serum concentrations of AZA were below 1 μg/mL in human subjects treated with conventional oral AZA doses (0.5–2.5 mg/kgbw/day) [24], and the maximal serum levels in mice were observed to be 11.3 μg/mL after a single oral dose of 33.3 mg/kgbw AZA [25]. To test both therapeutic and toxic concentrations of thiopurines, we chose to use the 1 and 10 μg/mL concentrations in most of the ex vivo experiments, while to assess the in vivo thiopurine exposure, 1.5 and 15 mg/kgbw in vivo doses were used. Briefly, mice received a daily dose (150 μL) of either thiopurine (1.5 or 15 mg/kgbw/day AZA, 6-MP, or 6-TG) or sterile physiologic saline as sham control, for one or four weeks through a 22 G gastric feeding tube (Instech Laboratories, PA, USA), respectively. After the oral treatment, mice were selected either for further experiments or immediate pancreas collection and cell isolation.
Measurement of in vivo pancreatic fluid secretion
The stimulated in vivo pancreatic juice-secretion was measured in ketamine-xylazine sedation, as previously described [26]. Briefly, through a narrow laparotomy, the duodenum and the head of the pancreas were exposed and the main pancreatic duct was cannulated with a blunted 26 G needle and fixated with a vascular clip. To avoid measuring the bile secretion, the ductus choledochus was also clipped carefully. Total pancreatic juice secretion was stimulated using IP 0,75 U/kgbw human secretin and the secreted volume was measured after 30 min with a 100 μL pipette and normalized to the animals' bodyweight and time.
Isolation of pancreatic acinar cells and ductal fragments
Mouse pancreatic acinar cell clusters were isolated as previously described [27, 28], with some adaptations. Briefly, the collected pancreas was minced into 1–3 mm3 pieces and placed in ice-cold HBSS. Lipids and fats were removed by centrifugation at 450 × g for 2 min. Tissue pieces were digested in 5 mL freshly prepared HBSS solution containing 200 units/ml collagenase, 10 mM HEPES and 0.25 mg/ml trypsin inhibitor at 37 °C for 20–30 min. Digested tissue was washed with HBSS of 4 °C with 10 mM HEPES, 0.25 mg/ml soybean trypsin inhibitor, and 5% FBS, centrifuged 3 × for 2 min at 450 RCF (Rotor radius: 180 mm), and the pellet was filtered through a 100 μM cell mesh and resuspended in Medium-199 with 2.5% FBS and 0.25 mg/ml soybean trypsin inhibitor. Pancreatic ductal fragments were isolated as described previously [29, 30]. Briefly, mice were euthanized with pentobarbital, and the pancreas was removed, and placed into ice-cold DMEM/F12. The pancreas was injected with a digestion medium (DMEM/F12 containing 100 U/ml collagenase, 0.1 mg/ml trypsin inhibitor, and 1 mg/ml bovine serum albumin) and was incubated in a shaking water bath at 37ºC for 30 min. Small intra- and interlobular ducts were identified and were mechanically dissected from the acini under a stereomicroscope.
Preparation mouse pancreatic organoid culture
Mouse pancreatic ductal organoids were generated as previously described [22, 29]. Briefly, the mouse pancreas was minced into small fragments and incubated for 1 h at 37 °C in a digestion media containing collagenase IV and dispase. After digestion, the tissue was washed and resuspended in Matrigel Basement Membrane Matrix and plated in domes and kept in culture (at 37 °C 95% relative humidity, and 5% CO2) by changing media every other day. Organoids were used for experiments between passage number 2 and 5. For the experiments, organoids were digested into single cells TrypLE Express and after 60 min of recovery time, they were incubated in 6-well plates with drug/inhibitor-containing or control culture media for another 60 min.
Measurement of intracellular pH, Ca2+, and Cl– changes by fluorescence microscopy
Fluorescence microscopy measurements were taken as previously described [21,22,23]. Isolated pancreatic acini or ductal fragments were attached to a poly-L-lysine coated cover glass, placed in a perfusion chamber, and incubated with MQAE (2 μM), Fura 2-AM (5 μM), or BCECF-AM (2 μM) in HEPES solution for 30 min at 37 °C with 5% CO2. After incubation, chambers were mounted on an Olympus IX73 inverted microscope (Olympus, Japan) and were perfused continuously at a constant speed with extracellular solutions heated to 37 °C. Microscopes were equipped with LED illumination systems (Olympus CoolLED PE-4000 and pE-340Fura2) and matching dichroic filters. A Hamamatsu Orca-Flash 4.0 CCD camera (Hamamtsu Photonics, Japan) and an Olympus 20× water immersion objective (NA: 0.8) were used for capturing fluorescent signals with a temporal resolution of 1 s using the Olympus Excellence software. To test the effect of thiopurines and inhibitors we changed the perfusion from control solutions to thiopurine and/or inhibitor-containing buffered solutions for 10 min before and during performing the stimulations described below. The first n number defines the number of animals, the second is the number of independent experiments and the third is the number of acinar cells/ductal fragments analyzed.
Intracellular Ca2+ signals ([Ca2+]i) were measured as described previously [22, 29], during the continuous recording of the fluorescent signal captured from acinar cells, as well as from PDEC loaded with FURA-2 dye. One region of interest (ROI) was placed on one acinar cell, therefore the number of ROIs is the same as the acinar cell numbers. The cells were continuously perfused either with control or 100 nM Carbachol containing standard HEPES solutions (Table 2). The fluorescence signals were normalized and expressed as relative fluorescence (F/F0).
To estimate the Cl– secretory activity of PDEC, we continuously monitored the intracellular Cl– concentration ([Cl–]i) of the ductal fragments with the help of the Cl–-sensitive fluorescent dye MQAE, during continuous perfusion with HCO3–/CO2–-buffered solutions. The loaded cells were excited with 340 nm. The increase in the fluorescent intensity reflects a decrease in the intracellular Cl− concentration. Initially, ductal fragments were perfused with standard HEPES solutions for a brief period to wash out the excess fluorescent dye, then the perfusion was changed to standard HCO3–-solution (Table 2). After reaching a steady-state fluorescent signal, the extracellular Cl– was removed by switching to Cl–-free HCO3−-solution (Table 2). The removal of extracellular Cl– induces a rapid elevation in fluorescence intensity equivalent to a decrease in [Cl–]i, and the relative amplitude of this change is proportionate to the luminal Cl– efflux mediated by CFTR. The fluorescence signals were normalized and expressed as relative fluorescence (F/F0).
Recovery from an alkaline load. Initially, ductal fragments were perfused with standard HEPES solutions for a brief period to wash out the excess fluorescent dye, then the perfusion was changed to standard HCO3–-solution (Table 2). Then, during continuous perfusion with HCO3–/CO2-buffered solutions, we monitored the changes in intracellular pH (pHi). During alkaline loading, ductal fragments were exposed to 20 mM NH4Cl from the basolateral side, where the passive influx of NH3 triggered a rapid alkalosis of the pHi, followed by a decaying recovery (downward-tilted arrows in Figs. 3A, 4A, D) created by the active efflux of HCO3– through luminal SLC26A and CFTR proteins. The initial rates of recovery (dpHi/dt) over 30 s from the highest pHi levels were calculated and converted to base flux values (B–/min) using calibration data from previously published measurements [21, 29, 31].
Recovery from an acid load. Ductal fragments were loaded with NH4Cl as described above. The removal of NH4Cl from extracellular solution resulted in an unfacilitated NH3 efflux, which triggered rapid acidification in the pHi, followed by a decaying increase in the pHi (upward-tilted arrows in Figs. 3A, 4A, D) created by the active influx of HCO3– and the active efflux of H+ through the basolateral NBCe1 and NHE1&4 proteins, respectively. The initial rates of recovery (dpHi/dt) over 60 s from the lowest pHi levels were calculated and converted to base flux values (B–/min) using calibration data from previously published measurements [21, 29, 31].
Immunostaining
Immunofluorescent labeling on sectioned ductal fragments was performed as previously described [29]. Briefly, isolated pancreatic ductal fragments and organoids were frozen in Shandon Cryomatrix at -20 °C. The 7-μm thick sections were placed on microscope slides, and fixation was performed with 4% PFA-PBS for 20 min followed by washing for 3 × 5 min with PBS. After permeabilization in citrate/Triton-X 100, the sections were blocked with 0.1% goat serum and 10% BSA in PBS for 2 h. The overnight incubation with primary CFTR (rabbit, monoclonal) antibodies at 4 °C was followed by repeated washing steps after which secondary (goat anti-rabbit Alexa Fluor 488) antibodies were added for 2 h at room temperature. Nuclear staining and mounting were carried out simultaneously by ProLong™ Gold Antifade mounting medium with DAPI. Images were captured with a Zeiss LSM880 confocal microscope using a 40× oil immersion objective (Plan-Apochromat 40×/1.4 Oil DIC M27; Zeiss, Germany). For the semiquantitative analysis, images were captured with the same setup from 5 different ductal fragments per group, derived from at least 2 different mice. On each image, CFTR fluorescence intensity profiles were determined over 4.5 μm long vectors at every 30 μm all around the identified luminal cavities, starting from the luminal side. Linear profiles were determined using the FIJI software (NIH, USA), peak intensity was noted in arbitrary units (AU), and peak distance from the lumen, as well as peak width (measured at half-maximal intensity), was calculated. The peak distance value was calculated starting from the first point with an intensity of less than 0.3 AU.
Direct stochastic optical reconstruction microscopy (dSTORM)
Primary mouse pancreatic ductal cells were generated for dSTORM by digesting and plating mouse pancreatic ductal organoids on cover glass followed by incubation for 60 min with 1 μg/mL AZA-containing media. Organoids were fixed with 4% PFA in PBS for 10 min and antigen retrieval was performed with 0.01% Triton-X-100 in PBS for 10 min. Specific binding sites were blocked by applying 10% BSA in PBS for 2 h at 37 °C. CFTR and ezrin primary antibodies (1:100) were applied during overnight incubation at 4 °C and fluorophore-conjugated secondary antibodies were applied (mouse anti-rabbit Alexa Fluor 647 and goat anti-rabbit Alexa Fluor 568). Cover glasses were placed in blinking buffer (which contains 100 U glucose oxidase, 2000 U catalase, 55.5 mM glucose, and 100 mM cysteamine hydrochloride in 1 mL final volume with sterile PBS) and dSTORM images were captured by Nanoimager S (Oxford Nanoimaging ONI Ltd., UK). Cluster analysis of dSTORM images was evaluated by CODI (Oxford Nanoimaging ONI Ltd., UK). A channel-independent cluster analysis was performed based on the collected and individually recorded blinking events. Clusters were defined using a diameter of 120 nm from the center. The number of homogeneous and double-positive clusters was determined by examining the composition of individual clusters.
Biochemical assays
RAC1 Activity. Mouse pancreatic organoids were digested into single cells using TrypLE™ Express and incubated at 37 °C with 1 μg/mL AZA, 10 μM Ehop-016, or both for 60 min. Cell lysates were harvested and RAC1 activity was determined with a colorimetric RAC1 G-LISA kit (Cytoskeleton, USA) following the manufacturer’s protocol. Briefly, the assay utilizes Rac-GTP-binding protein immobilized to the bottom of a 96-well plate, which specifically binds to the active GTP-bound Rac1, while the inactive GDP-bound Rac1 is not interacting with the binding protein and is removed during washing. Then the active Rac1 is quantified with a Rac1-specific antibody. The degree of Rac1 activation is calculated from the ratio of the activated cell lysates and inactive cell lysates.
Amylase release assay. Freshly isolated acinar cells were seeded to 48-well plates and incubated for 30 min at 37 °C with supplemented Medium-199, then 1 μg/mL AZA and/or 100 nM cerulein-containing media was added, and cells were incubated for another 60 min. After incubation, aliquots were taken from the supernatant and frozen instantly in liquid nitrogen to calculate the released amylase activity. Then, Triton X-100 was added in a final concentration of 1% to the remaining cell suspension, incubated for 15 min, centrifuged at 450 × g for 3 min, 4 °C, and a second aliquot was frozen in liquid nitrogen to calculate the total amylase activity. Both activities of released and total amylase were determined for each sample using an EPS method-based[32] Alpha-Amylase Kit (Diagnosticum Zrt., Hungary) on a CLARIOStar plate reader at 405 nm (BMG Labtech, Germany) following the manufacturer's protocol, and the percentage of released amylase was calculated.
Measurement of cell viability
Freshly isolated acinar cells were incubated for 30 min with supplemented Medium-199 in 48-well plates (Greiner Bio-One, Hungary), then AZA containing (0.1–1-10–100-1000 μg/mL) media was added, and cells were incubated for another 60 min at 37 °C. Cerulein (100–1000 nM) was applied as positive control. We determined the intracellular ATP content, which is proportional to the number of viable cells, using the CellTitre-Glo 3D (Promega) luminometric assay on a CLARIOStar plate reader. The total protein amount was determined using by Bradford assay in Spectrophotometer (Thermo Scientific™ NanoDrop™ One). Blank-corrected data were normalized to the total protein amount.
In addition, living, apoptotic, and necrotic cells were stained in 8-well chamber slides (Sarstedt, Germany) with Apoptosis-Necrosis Kit (Abcam) and were visualized under a Zeiss LSM880 confocal microscope using a 40× oil immersion objective (Zeiss, NA: 1.4). The total number of cells was calculated in FIJI (NIH, USA) using the built-in Cell Counter plugin and the ratio of the live, apoptotic and necrotic cells were given as the % of the total cell number.
Statistical analysis, post-tests
All experimental data were expressed as means ± SD. One-way ANOVA followed by Sidak’s post hoc test was used for multiple group comparisons. The chi-square test was used for the comparison of frequencies. T-test was used for pairwise comparisons. Two-way ANOVA with Tukey’s post hoc test was used for comparisons of multiple groups split by independent variables. P < 0.05 was accepted as being significant. All authors had access to the study data, and reviewed and approved the final manuscript.
Results
AZA treatment increases pancreatic damage in the early phase of cerulein-induced pancreatitis in mice
First, we wanted to model TIP in an in vivo animal model. To achieve this, mice were treated per os with 1.5 mg/kgbw/day AZA (a conventional human daily dose, [33]) for 1 week, then moderate AP was induced by 8 × 50 μg/kgbw IP cerulein injections. When the mice were sacrificed 4 h after the last cerulein injection, we were not able to observe any significant changes in the severity of AP in the AZA pre-treated group, as neither the average histological scores (Fig. 1A, B) nor the average serum amylase activities (Fig. 1C) of the cerulein-treated groups were significantly different. Also, when the mice were terminated 1 h after the last cerulein injection, the extent of interstitial edema, leukocyte infiltration, average pancreas weight/body weight ratio, or serum amylase activity were not significantly different in the cerulein-treated groups (Fig. 1D-G). However, the extent of necrosis was significantly higher in the AZA + cerulein-treated group compared to cerulein-treated groups (Fig. 1E). To test the effects of AZA on the severity of AP in an independent model, AP was also induced by 2 hourly injections of 1.35 g/kgbw ethanol + 150 mg/kgbw palmitoleic acid (POA) after 1 week per os 1.5 mg/kgbw/day AZA treatment. The animals were sacrificed 24 h after the first ethanol + fatty acid injection. Similarly to the results from the cerulein-induced model, there are no significant differences were observed in histological parameters (Suppl. Figure 1A-B), serum amylase level (Suppl. Figure 1C), and pancreas weight/body weight ratio (Suppl. Figure 1D) between ethanol + AZA-treated and alone ethanol-treated mice. These results suggest that we successfully modeled the effect of AZA treatment on the exocrine pancreas, which can increase tissue damage in the early phase of AP the disease.
AZA has no detectable effect on pancreatic acinar cells in mice
Premature activation of digestive enzymes due to pancreatic acinar cell injury and necrosis is a hallmark of AP with different etiologies, including forms of DIAP [34]. AZA is known to induce apoptosis in immune cells via a caspase-9-dependent pathway [35], therefore, we next investigated the effect of AZA on pancreatic acinar cell viability. For this, we incubated isolated pancreatic acinar cells with clinically relevant (0.1–1 μg/mL) and toxic (10–1000 μg/mL) concentrations of AZA for 60 min at 37ºC. None of the applied AZA concentrations were found to cause any significant change in the proportion of the living acinar cells, evaluated with a luminescence-based ATP assay (CellTitreGlo 3D) compared to the positive control cerulein (Fig. 2A). Then, to compare acute and chronic AZA exposure we determined the proportion of viable, apoptotic, and necrotic/late apoptotic acinar cells after incubation with 1 μg/mL AZA for 1 h at 37ºC using an apoptosis/necrosis detection kit. In addition, we also isolated pancreatic acinar cells from in vivo AZA-treated mice using the same conditions as above (Fig. 2B, C). According to these experiments, AZA had no effect on the acinar cell viability either upon per os or ex vivo exposure. In contrast, the positive control cerulein markedly reduced the viability of the acinar cells as expected.
Most pancreatitis-inducing agents trigger acinar cell damage via sustained intracellular Ca2+ elevation [36, 37], whereas AZA was also found to increase the cytosolic Ca2+ levels ([Ca2+]i) in blood cells [38]. Therefore in the next step, we analyzed the effect of AZA treatment on the Ca2+ homeostasis of acinar cells. In these series of experiments, no effect of AZA was found on the Ca2+ signaling in acinar cells. The 10 min ex vivo perfusion of isolated pancreatic acinar cells with 1 μg/mL AZA was not sufficient to trigger Ca2+ signals (Fig. 2D), whereas the response of acinar cells to 100 nM carbachol in the presence of AZA was not altered (Fig. 2E, F). Similarly, we also could not observe any altered acinar Ca2+ signals after the 1-week-long in vivo AZA treatment.
Finally, to exclude the possible effect of AZA on pancreatic acinar cell functions, we determined the proportion of released amylase from the acinar cells. Cerulein was used as a positive control. In this series of experiments neither 60 min of incubation with 1 μg/mL AZA nor 1-week per os treatment with 1.5 mg/kgbw AZA was sufficient to induce amylase release (Fig. 2G). The co-stimulation of acinar cells with AZA and cerulein caused a moderate, but significant increase in amylase release compared to cerulein stimulation alone. On the other hand, the per os AZA-treated acinar cells did not recapitulate this effect. These results support that AZA has no pathophysiologically relevant effect on the pancreatic acinar cells.
Thiopurines impair mouse pancreatic ductal HCO3 – secretion ex vivo
Pancreatic ductal cells secrete an alkaline fluid, which plays a major role in the maintenance of exocrine pancreatic homeostasis [22, 39]. As acinar cells were not affected by AZA, we wanted to assess the possible effect of AZA on the ductal cells. To estimate the HCO3– transport in PDEC, we perfused isolated pancreatic ductal fragments with 1 and 10 μg/mL AZA for 10 min and found that the base flux values were significantly decreased during recovery from alkaline and acid load (Fig. 3A-C). The inhibitory effect was not dose-dependent in the investigated concentration range. Active metabolites of AZA (6-MP and 6-TG) were also reported to induce DIAP [40, 41], therefore, we tested the effect of all thiopurines on ductal HCO3– secretion by perfusing the ductal fragments with 1 μg/mL 6-MP and 6-TG, respectively. Similar to AZA treatment, the base flux values during recovery from alkaline and acid load were significantly reduced by both 6-MP and 6-TG perfusions compared to controls (Fig. 3A-C). These results suggest that AZA and its active metabolites disturb the apical and basolateral HCO3– transport processes in pancreatic ductal cells.
Thiopurines impair pancreatic ductal HCO3 – secretion in vivo in mice
To investigate, whether the ex vivo observed effects could also be seen in a clinically more relevant experimental setup, we treated mice orally in vivo both with therapeutic (1.5 mg/kgbw/day) [42] and non-lethal toxic (15 mg/kgbw/day) [25] AZA doses for one week. To gain information about the exocrine pancreatic HCO3– secretion, we isolated pancreatic ductal fragments and conducted the above-described fluorescent measurements. Our results demonstrated that one-week per os AZA treatment, either with therapeutic or toxic doses, significantly impaired the base fluxes of both recoveries (i.e., from alkaline or acid loads) compared to untreated control mice (Fig. 4A-C), indicating that the inhibitory effect of AZA is present after in vivo treatment as well. In addition, we also treated animals with the other two thiopurines for 1 week with 1.5 mg/kgbw daily doses. The one-week-long treatment with 6-MP and 6-TG both recapitulated the effects of the AZA treatment and significantly decreased the base flux values during recovery both from alkaline, as well as from acid loads (Fig. 4D-F). The magnitude of inhibition was not significantly different among the three thiopurines (Fig. 4E, F). This indicates that the inhibitory effect of thiopurines is not dependent on the specific conformational differences between the drugs, but it is rather a common property of all thiopurines. To assess whether the thiopurine-induced decrease of the ductal HCO3– secretion diminishes the pancreatic fluid secretion, we measured the total pancreatic juice secretion in vivo in anesthetized mice. After 1 week of per os treatment with either 1.5 mg/kgbw/day AZA or 6-MP, the secretion rates were significantly reduced in both cases compared to sham controls (Fig. 4/G). Our results demonstrate that AZA and its metabolites inhibit the pancreatic HCO3– and fluid secretion in vivo.
AZA decreases the apical CFTR expression and CFTR-mediated Cl– secretion in pancreatic ductal cells
Previously we demonstrated that pancreatitis-inducing agents, such as bile acids or non-oxidative ethanol metabolites, inhibit the pancreatic ductal HCO3– secretion via sustained intracellular Ca2+ elevation [21, 43]. To test whether this mechanism plays a role in the inhibitory effect of AZA, we assessed the intracellular Ca2+ homeostasis of pancreatic ductal cells in the presence of AZA. Similarly to acinar cells, we could observe no significant changes either in the baseline [Ca2+]i levels during the 10-min perfusion with 1 μg/mL AZA, or in the maximal response to 100 nM carbachol stimulation after the AZA perfusion, compared to controls (Fig. 5A, B), suggesting that AZA does not have a major influence on ductal Ca2+ homeostasis. On the other hand, in alcohol-induced AP, a marked reduction of the apical CFTR expression and function is observed as a highlight of the toxic effect of ethanol on the ductal cells [21]. To test whether the inhibitory effects of AZA on HCO3– secretion are caused by disturbed CFTR expression or function, we analyzed the intracellular localization of CFTR with immunofluorescent staining. Our results showed that both incubation of ductal fragments with 1 μg/mL of AZA for 60 min ex vivo, or 1 week of per os treatment with 1.5 mg/kgbw AZA significantly diminished the predominantly apical staining of CFTR and triggered the retention of the protein into the cytosol (Fig. 5C, D). Then, we tested whether the disturbed apical CFTR expression also pairs with impaired Cl− secretion. To investigate this, we examined the CFTR-dependent Cl– secretion transport of the ductal epithelia. In these experiments, both the 10 min acute exposure of the ductal fragments to 1 μg/mL AZA, as well as the 1-week-long per os treatment with 1.5 mg/kgbw AZA impaired the luminal Cl– efflux significantly compared to untreated controls. Importantly, the selective CFTR inhibitor CFTR(inh)-172 caused a similar inhibition of the CFTR-mediated Cl– transport to that caused by AZA (Fig. 5E, F). Notably, our results revealed that AZA treatment diminishes the apical CFTR expression and significantly impairs the function of CFTR in pancreatic ductal cells.
AZA disrupts CFTR plasma membrane retention in PDEC by inhibiting RAC1 and ezrin in mice
Finally, we wanted to understand the mechanism of the AZA-induced decrease in CFTR plasma membrane localization and function. It is well-described that CFTR is tethered to the apical plasma membrane by a scaffolding protein complex, comprising Na+/H+ exchanger regulating factor (NHERF) family members and the actin cytoskeleton adaptor protein, ezrin [44,45,46]. Ezrin was also shown to play a role in the Protein-kinase-A-mediated regulation of CFTR [47]. Previously, AZA was suggested to inhibit RAC1 [35, 48], an activator of ezrin [44], which may play a role in the effects of AZA in ductal cells. To investigate the role of RAC1 and ezrin in the AZA-induced CFTR dysfunction, we first administered RAC1 (Ehop-016), and ezrin (NSC668394) inhibitors for 10 min to isolated ductal fragments, and measured the Cl–-efflux. Interestingly, both ezrin and RAC1 inhibitors recapitulated the effect of AZA on ductal Cl– secretion (Fig. 6A, B). To further validate our hypothesis, mouse pancreatic organoids were used to measure RAC1 activity in ductal cells. As organoids contain epithelial cells only, no contamination of other cell types is expected [29], which may disturb RAC1 activity measurement. For this assay, the organoids were digested into single cells as previously described [23] and were incubated with 1 μg/mL AZA for 60 min, which significantly decreased the amount of active RAC1 in a G-LISA assay (Fig. 6C). Notably, the RAC1 inhibitor Ehop-016 was not able to further decrease the activity of RAC1 in the presence of AZA. Finally, we used super-resolution direct stochastic optical reconstruction microscopy (dSTORM) to quantify the colocalization of CFTR and ezrin in adherent primary epithelial cells derived from mouse pancreatic organoids. The STORM images clearly demonstrated that AZA treatment significantly decreased the number of colocalizing ezrin-CFTR clusters compared to the control cells (Fig. 6D). To quantify this decrease, cluster analysis was performed, as shown (Fig. 6E). First, the total number of localizations, then the number of the double-positive clusters was determined and given as the % of the total cluster numbers. The performed cluster analysis confirmed that incubation of the cells with 1 μg/mL AZA for 60 min markedly decreased the colocalizing probability (OR = 0.18; 95% CI 0.17 – 0.40; P < 0.001) of ezrin and CFTR compared to the control (Fig. 6F). To confirm these results, subcellular fractionation and western blot for ezrin and CFTR were performed. These results suggest that the level of ezrin is impaired in the cytoskeletal fraction, whereas the level of CFTR is decreased in the membrane and cytosolic fraction, which supports our observation with the dSTORM (Suppl. Figure 2). These results confirm that the impaired plasma membrane localization of CFTR in the AZA-treated ductal cells is caused by the inhibition of RAC1, which disturbs the CFTR-ezrin interaction leading to decreased plasma membrane tethering and loss of CFTR expression, which consequently impairs the CFTR function.
Discussion
In this study, we used different ex vivo and in vivo model systems and explored the pathomechanism of TIP, which is one of the most common side effects of AZA treatment among IBD patients. Our results showed that in vivo AZA treatment increases tissue damage in the early phase of the cerulein-induced AP in mice. AZA and its metabolites impaired the expression of CFTR in the apical plasma membrane of pancreatic ductal cells via RAC1 inhibition and disruption of CFTR-ezrin interaction, leading to a consequent decrease in the exocrine pancreatic ion and fluid secretion. Notably, AZA had no primary effect on the pancreatic acinar cells.
The spectrum of adverse events during thiopurine treatment is wide, ranging from digestive intolerance, alopecia, leukopenia, and hepatotoxicity to TIP [10, 11]. Several studies, mostly with a clinical approach, tried to investigate the pathophysiology of TIP and suggested immune-mediated and genetics-associated mechanisms [15, 49]. They also mention the potential role of direct toxic mechanisms but the molecular background remains unexplored [15]. Clinical studies usually report TIP during the first 30 days of treatment [14, 41, 50]. In our study, we demonstrated that daily administration of AZA for a week has no visible effect on the exocrine pancreatic morphology in mice. On the other hand, when the mice were challenged with cerulein, the tissue damage in the early phase of the AP was significantly increased in the AZA-treated group suggesting that AZA treatment may have direct effects on the exocrine pancreas. Eventually, this phenomenon may be influenced by the immunosuppressant effect of thiopurines as well. Previously, Kerstein et al. reported amelioration of experimental pancreatitis in dogs by administration of AZA [51]. Nevertheless, our data suggest that AZA treatment increases the exocrine pancreatic damage in the presence of other stimuli that may underlie the clinically observed features of TIP.
Next, we wanted to assess the mechanism leading to the increased damage of the cerulein-stimulated exocrine pancreas. The most common pancreatitis-inducing agents, such as ethanol and bile acids, affect the pancreatic acinar [52] and ductal cells [21]. Ethanol and non-oxidative ethanol metabolites and bile acids were previously described to trigger sustained intracellular Ca2+ elevation and mitochondrial damage in pancreatic acinar and ductal cells, leading to intra-acinar trypsinogen autoactivation and impaired ductal secretion, respectively [21, 43]. Moreover, similar intracellular events were described in the case of Asparaginase-induced AP [6]. Previously, Foitzik et al. showed that treatment either with supra-clinical doses of AZA (10 mg/kgbw/day) or different doses of cyclosporine A, administered 6 h after the AP-induction, caused more extensive acinar cell necrosis in rats [53]. In addition, Geiger et al. showed that incubation with the toxic concentrations (5 and 10 μg/mL, respectively) of AZA elevated the intracellular Ca2+ level and phosphatidylserine exposure of human erythrocytes, but not with the clinically more relevant 2 μg/mL AZA concentration [38]. In our experiments, AZA had no detectable effect on the viability of pancreatic acinar cells when used in a clinically relevant concentration range. Accordingly, no alterations were registered in the intracellular Ca2+ homeostasis or amylase release of pancreatic acinar cells. These data suggest that in contrast to the previous findings, AZA has no visible effect on pancreatic acinar cells in clinically relevant concentrations. This aligns well with the clinical observation that the majority of AP cases during thiopurine treatment are mild to moderate, whereas severe cases are rarely reported [54].
Another possible target of pancreatitis-inducing factors are the pancreatic ductal epithelial cells [36, 37], which secrete the HCO3–-rich, alkaline pancreatic juice that washes the digestive enzymes out from the pancreatic tree thus preventing premature trypsinogen autoactivation [55]. The HCO3– secretion is mediated by the interplay of the basolateral Na+-HCO3– co-transporters (NBCe1-B), the luminal Cl–/HCO3– exchangers (SLC26A3,6), CFTR channels, and the ubiquitous Na+/H+ exchanger proteins (NHE1-4) [29, 39, 56]. Of these proteins, CFTR seems to play a central role in pancreatic diseases [57, 58]. Our group has demonstrated previously that ethanol and fatty acid treatment directly reduced the expression and activity of CFTR, impaired ductal HCO3– secretion, and led to increased severity of experimental AP in mice [21]. Also, genetic deletion of Na+/H+ exchanger regulatory factor-1 (NHERF1) – a member of a protein complex tethering CFTR to the apical membrane [45] – has also been shown to cause CFTR mislocalization in PDEC and decreased ductal secretory activity leading to a more severe experimental AP [39]. Early studies of the effect of AZA on canine exocrine pancreatic secretion from the 1980s provided controversial results. In a preliminary study, Dreiling et al. found that co-administration of intravenous AZA (100 mg) and hydrocortisone (1 mg) significantly decreased the pancreatic juice flow in dogs [59], while Broe et al. reported that infusions with both 0,5 and 5 mg/kgbw AZA increased the pancreatic flow and HCO3– output in ex vivo canine pancreas preparations [60]. In our study, we provided clear evidence that both ex vivo and in vivo thiopurine treatment (AZA and its metabolites) decreases pancreatic ductal HCO3– and fluid secretion in mice, in clinically relevant concentrations. Notably, for the in vivo administration, we used oral gavage feeding that completely recapitulates the pharmacokinetics of the usual clinical (oral) administration of AZA. Here, we also showed that thiopurine treatment impaired the basolateral (i.e., NHE and NBCe1) and apical ion transport activities, respectively. Previously, Bhandaru et al. found no effect of AZA on basolateral NHE in dendritic cells when AZA was applied in 2.77 μg/mL. This may suggest that the impaired basolateral transport activities may be secondary due to the damaged apical transport processes, however, we did not explore this phenomenon further in the current study.
To further characterize the inhibition of HCO3– secretion caused by thiopurines, we analyzed the apical CFTR expression and activity of pancreatic ductal cells in the presence of AZA. CFTR channels can be found almost exclusively on the apical membrane of pancreatic ductal cells [56]. The CFTR-mediated Cl– and HCO3– transport represents a rate-limiting step in epithelial anion secretion, therefore, controlling transepithelial fluid secretion and ultimately the hydration of the epithelial luminal surfaces [61]. Several mutations of the CFTR gene lead to impaired ion channel function and consequently impaired epithelial fluid transport in organs such as the lung and the pancreas. While homozygous carriers of CFTR mutations generally develop cystic fibrosis, heterozygous carriers do not necessarily; however, they often exhibit an increased risk for pancreatitis and associated pancreatic damage characterized by elevated mucus levels, fibrosis, and cyst formation [61]. Furthermore, recent studies demonstrated that not only genetic mutations but other pancreatitis-causing insults, such as alcohol, smoking, or bile acids, can inhibit CFTR-dependent epithelial functions. Here, we also demonstrated that AZA exposure decreases the apical plasma membrane expression of CFTR, moreover the Cl– secretion of ductal fragments was also significantly impaired by AZA, applied either ex vivo or in vivo. These results suggest that AZA treatment consequently diminishes CFTR function as well due to the impaired channel expression.
Finally, we wanted to clarify the mechanism of action through which AZA inhibits CFTR activity and expression. Multiple studies showed, that the inhibited ductal secretory functions and CFTR activity are at least partly a result of toxic Ca2+ overload in ductal epithelial cells [21, 22, 43, 62]. However, similar to acinar cells, we could find no altered Ca2+ signals in PDEC during AZA treatment, suggesting a Ca2+-independent inhibitory effect of AZA. CFTR is a member of a large plasma membrane protein complex consisting of several proteins [63]. The apical localization of CFTR in secretory epithelial cells is maintained by a scaffolding protein complex comprised of CFTR, NHERF1, ezrin, and actin [39, 64]. Ezrin is regulated by RAC1 [44], and stimulation of RAC1 has been shown to restore F508del-CFTR expression and functions in human bronchial epithelial cells [64]. Furthermore, in a previous study, AZA was suggested to inhibit RAC1 in T lymphocytes [20]. Here, we demonstrated that AZA not only inhibits RAC1 activity in PDEC but leads to impaired colocalization of ezrin and CFTR, which eventually affects the plasma membrane distribution of CFTR in mouse ductal fragments. Importantly, this observation provides a detailed molecular mechanism that could explain the impaired pancreatic ion and fluid secretion observed in AZA-treated animals.
To our knowledge, this is the first study that describes the effect of AZA on the exocrine pancreas applied in a clinically relevant setting. Although the impaired apical CFTR expression and activity observed in pancreatic ductal cells could potentially contribute to the increased sensitivity of the exocrine pancreas to other stress factors, so far clinical studies mostly highlighted only the immunologic and genetic mechanisms of TIP [49, 65]. Other serious adverse events of thiopurine usage, such as myelosuppression, are associated with thiopurine methyltransferase polymorphisms, but such an association has not been shown in the case of TIP [12]. Heap et al. identified a strong association between Class II HLA variants and susceptibility to TIP in IBD patients [49], which is in support of immune-mediated mechanisms. Another interesting finding is that TIP is observed in a higher percentage of IBD patients – especially in Crohn’s disease – than in any other patients treated with AZA [50, 54, 66]. Although these studies are supporting that immunologic processes would play an important role in TIP, exact mechanisms behind this hypothesis are not yet found, while the direct effects of AZA on CFTR activity presented in our study gives the first mechanistic insight into the pathogenesis of TIP which may open new directions in the prevention of this important adverse event. Recently, personalized evaluation of thiopurines based on pharmacogenetics in a recent study was successful to prevent myelotoxicity; however, it failed in the prevention of TIP [67]. CFTR functions, however, can be easily assessed in rectal biopsies and rectal organoid cultures offering personalized treatment options in patients with cystic fibrosis [68]. Similar approaches might prove useful in the prevention of TIP to screen patients with decreased CFTR activity, given that colonoscopy is routinely performed in the clinical follow-up of IBD patients. Furthermore, cystic fibrosis drives intense research to identify novel drugs to modify CFTR activity [69], which also holds the potential to be utilized in the prevention of TIP.
Taken together, in mice, we explored the mechanism of action of AZA on the exocrine pancreas, which exclusively affected the secretory activity of pancreatic ductal cells. The RAC1 inhibition by thiopurines led to an impaired ezrin-CFTR interaction and disturbed CFTR expression on the apical plasma membrane of the pancreatic ductal cells. Our observations may be relevant not only in the pancreas but in other secretory organs as well.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on request.
Abbreviations
- 6-MP:
-
6-Mercaptopurine
- 6-TG:
-
6-Thioguanine
- 6-TGNs:
-
6-Thioguanine-nucleotides
- AZA:
-
Azathioprine
- AP:
-
Acute pancreatitis
- AU:
-
Arbitrary unit
- kgbw:
-
Body weight in kilograms
- BCECF-AM:
-
2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester
- [Ca2+]i :
-
Intracellular Ca2+ level
- CFTR:
-
Cystic fibrosis transmembrane conductance regulator
- [Cl–]i :
-
Intracellular Cl– level
- DIAP:
-
Drug-induced acute pancreatitis
- dSTORM:
-
Direct stochastic optical reconstruction microscopy
- EPS:
-
4,6-Ethylidene(G1)-4-nitrophenyl(G7)-a-(1–4)-D-maltoheptaoside
- FURA2-AM:
-
Fura-2-acetoxymethyl ester
- IBD:
-
Inflammatory bowel disease
- IP:
-
Intraperitoneal
- MQAE:
-
N-(Ethoxycarbonylmethyl)-6-methoxyquinolinium bromide
- NHE:
-
Na+/H+ exchanger
- NHERF1:
-
Na+/H+ exchanger regulatory factor-1, SLC9A3R1
- NBC:
-
Na+-HCO3–co-transporters
- PDEC:
-
Pancreatic ductal epithelial cell
- pHi :
-
Intracellular pH
- RAC1:
-
Ras-related C3 botulinum toxin substrate
- SLC26:
-
Solute carrier family 26
- TIP:
-
Thiopurine-induced acute pancreatitis
References
Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS (2019) Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156(1):254-272e11. https://doi.org/10.1053/j.gastro.2018.08.063
Parniczky A, Kui B, Szentesi A, Balazs A, Szucs A, Mosztbacher D, Czimmer J, Sarlos P, Bajor J, Godi S, Vincze A, Illes A, Szabo I, Par G, Takacs T, Czako L, Szepes Z, Rakonczay Z, Izbeki F, Gervain J, Halasz A, Novak J, Crai S, Hritz I, Gog C, Sumegi J, Golovics P, Varga M, Bod B, Hamvas J, Varga-Muller M, Papp Z, Sahin-Toth M, Hegyi P, Hungarian Pancreatic Study G (2016) Prospective, multicentre, nationwide clinical data from 600 cases of acute pancreatitis. PLoS One 11(10):e0165309. https://doi.org/10.1371/journal.pone.0165309
Nitsche C, Maertin S, Scheiber J, Ritter CA, Lerch MM, Mayerle J (2012) Drug-induced pancreatitis. Curr Gastroenterol Rep 14(2):131–138. https://doi.org/10.1007/s11894-012-0245-9
Abu-El-Haija M, Hornung L, Lin TK, Nathan JD, Thompson T, Vitale DS, Nasr A, Husain SZ, Denson L (2020) Drug induced pancreatitis is the leading known cause of first attack acute pancreatitis in children. Pancreatology 20(6):1103–1108. https://doi.org/10.1016/j.pan.2020.07.008
Meczker A, Hanak L, Parniczky A, Szentesi A, Eross B, Hegyi P, Hungarian Pancreatic Study G (2020) Analysis of 1060 cases of drug-induced acute pancreatitis. Gastroenterology 159(5):1958-1961e8. https://doi.org/10.1053/j.gastro.2020.07.016
Peng S, Gerasimenko JV, Tsugorka T, Gryshchenko O, Samarasinghe S, Petersen OH, Gerasimenko OV (2016) Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2. Philos Trans R Soc Lond B Biol Sci. https://doi.org/10.1098/rstb.2015.0423
Raja RA, Schmiegelow K, Frandsen TL (2012) Asparaginase-associated pancreatitis in children. Br J Haematol 159(1):18–27. https://doi.org/10.1111/bjh.12016
Peng S, Gerasimenko JV, Tsugorka TM, Gryshchenko O, Samarasinghe S, Petersen OH, Gerasimenko OV (2018) Galactose protects against cell damage in mouse models of acute pancreatitis. J Clin Invest 128(9):3769–3778. https://doi.org/10.1172/JCI94714
Chang JY, Cheon JH (2019) Thiopurine therapy in patients with inflammatory bowel disease: a focus on metabolism and pharmacogenetics. Dig Dis Sci 64(9):2395–2403. https://doi.org/10.1007/s10620-019-05720-5
Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A (2020) Thiopurines: recent topics and their role in the treatment of inflammatory bowel diseases. Front Pharmacol 11:582291. https://doi.org/10.3389/fphar.2020.582291
Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V, Bastida G, Penalva M, Gomollon F, Garcia-Planella E, Merino O, Gutierrez A, Esteve M, Marquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Munoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Cena G, Saro C, Aldeguer X, Barrio J, Mate J, Gisbert JP (2013) Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 19(7):1404–1410. https://doi.org/10.1097/MIB.0b013e318281f28f
Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, Carpio D, Lorenzo A, Castro J, Martinez-Ares D, Pereira S, Martin-Granizo I, Corton M, Carracedo A, Barros F (2011) A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving azathioprine. J Gastrointestin Liver Dis 20(3):247–253
Munk EM, Pedersen L, Floyd A, Norgard B, Rasmussen HH, Sorensen HT (2004) Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 99(5):884–888. https://doi.org/10.1111/j.1572-0241.2004.04123.x
Wintzell V, Svanstrom H, Olen O, Melbye M, Ludvigsson JF, Pasternak B (2019) Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. Lancet Child Adolesc Health 3(3):158–165. https://doi.org/10.1016/S2352-4642(18)30401-2
Ledder O, Lemberg DA, Day AS (2015) Thiopurine-induced pancreatitis in inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 9(4):399–403. https://doi.org/10.1586/17474124.2015.992879
Kim JW, Hwang SW, Park SH, Song TJ, Kim MH, Lee HS, Ye BD, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK (2017) Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol 23(19):3505–3512. https://doi.org/10.3748/wjg.v23.i19.3505
Bayoumy AB, Crouwel F, Chanda N, Florin THJ, Buiter HJC, Mulder CJJ, de Boer NKH (2021) Advances in thiopurine drug delivery: the current state-of-the-art. Eur J Drug Metab Pharmacokinet 46(6):743–758. https://doi.org/10.1007/s13318-021-00716-x
Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 64(8):753–767. https://doi.org/10.1007/s00228-008-0478-6
Marinkovic G, Kroon J, Hoogenboezem M, Hoeben KA, Ruiter MS, Kurakula K, Otermin Rubio I, Vos M, de Vries CJ, van Buul JD, de Waard V (2014) Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug. J Immunol 192(9):4370–4378. https://doi.org/10.4049/jimmunol.1302527
Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176(1):640–651. https://doi.org/10.4049/jimmunol.176.1.640
Maleth J, Balazs A, Pallagi P, Balla Z, Kui B, Katona M, Judak L, Nemeth I, Kemeny LV, Rakonczay Z Jr, Venglovecz V, Foldesi I, Peto Z, Somoracz A, Borka K, Perdomo D, Lukacs GL, Gray MA, Monterisi S, Zaccolo M, Sendler M, Mayerle J, Kuhn JP, Lerch MM, Sahin-Toth M, Hegyi P (2015) Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. Gastroenterology 148(2):427-439e16. https://doi.org/10.1053/j.gastro.2014.11.002
Pallagi P, Gorog M, Papp N, Madacsy T, Varga A, Crul T, Szabo V, Molnar M, Dudas K, Grassalkovich A, Szederkenyi E, Lazar G, Venglovecz V, Hegyi P, Maleth J (2022) Bile acid- and ethanol-mediated activation of Orai1 damages pancreatic ductal secretion in acute pancreatitis. J Physiol 600(7):1631–1650. https://doi.org/10.1113/JP282203
Madacsy T, Varga A, Papp N, Tel B, Pallagi P, Szabo V, Kiss A, Fanczal J, Rakonczay Z Jr, Tiszlavicz L, Razga Z, Hohwieler M, Kleger A, Gray M, Hegyi P, Maleth J (2022) Impaired regulation of PMCA activity by defective CFTR expression promotes epithelial cell damage in alcoholic pancreatitis and hepatitis. Cell Mol Life Sci 79(5):265. https://doi.org/10.1007/s00018-022-04287-1
Voogd CE (1989) Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutation Res/Rev Genetic Toxicol 221(2):133–152. https://doi.org/10.1016/0165-1110(89)90002-x
Lewis RJ (1996) Sax’s dangerous properties of industrial materials, 9th edn. Van Nostrand Reinhold, New York: NY
Perides G, van Acker GJ, Laukkarinen JM, Steer ML (2010) Experimental acute biliary pancreatitis induced by retrograde infusion of bile acids into the mouse pancreatic duct. Nat Protoc 5(2):335–341. https://doi.org/10.1038/nprot.2009.243
Geron E, Schejter ED, Shilo BZ (2014) Assessing the secretory capacity of pancreatic acinar cells. J Vis Exp. https://doi.org/10.3791/51799
Gout J, Pommier RM, Vincent DF, Kaniewski B, Martel S, Valcourt U, Bartholin L (2013) Isolation and culture of mouse primary pancreatic acinar cells. J Vis Exp. https://doi.org/10.3791/50514
Molnar R, Madacsy T, Varga A, Nemeth M, Katona X, Gorog M, Molnar B, Fanczal J, Rakonczay Z Jr, Hegyi P, Pallagi P, Maleth J (2020) Mouse pancreatic ductal organoid culture as a relevant model to study exocrine pancreatic ion secretion. Lab Invest 100(1):84–97. https://doi.org/10.1038/s41374-019-0300-3
Gray MA, Winpenny JP, Porteous DJ, Dorin JR, Argent BE (1994) CFTR and calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. Am J Physiol 266(1 Pt 1):C213–C221. https://doi.org/10.1152/ajpcell.1994.266.1.C213
Hegyi P, Rakonczay Z Jr, Gray MA, Argent BE (2004) Measurement of intracellular pH in pancreatic duct cells: a new method for calibrating the fluorescence data. Pancreas 28(4):427–434. https://doi.org/10.1097/00006676-200405000-00012
International Federation of Clinical C, Laboratory M, Schumann G, Aoki R, Ferrero CA, Ehlers G, Ferard G, Gella FJ, Jorgensen PJ, Kanno T, Kessner A, Klauke R, Kytzia HJ, Lessinger JM, Miller WG, Nagel R, Pauwels J, Schimmel H, Siekmann L, Weidemann G, Yoshida K, Ceriotti F (2006) IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Clin Chem Lab Med 44(9):1146–1155. https://doi.org/10.1515/CCLM.2006.212
Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2015(10):Cd000067. https://doi.org/10.1002/14651858.CD000067.pub3
Gerasimenko JV, Lur G, Ferdek P, Sherwood MW, Ebisui E, Tepikin AV, Mikoshiba K, Petersen OH, Gerasimenko OV (2011) Calmodulin protects against alcohol-induced pancreatic trypsinogen activation elicited via Ca2+ release through IP3 receptors. Proc Natl Acad Sci U S A 108(14):5873–5878. https://doi.org/10.1073/pnas.1016534108
Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111(8):1133–1145. https://doi.org/10.1172/JCI16432
Lee PJ, Papachristou GI (2019) New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol 16(8):479–496. https://doi.org/10.1038/s41575-019-0158-2
Habtezion A, Gukovskaya AS, Pandol SJ (2019) Acute pancreatitis: a multifaceted set of organelle and cellular interactions. Gastroenterology 156(7):1941–1950. https://doi.org/10.1053/j.gastro.2018.11.082
Geiger C, Foller M, Herrlinger KR, Lang F (2008) Azathioprine-induced suicidal erythrocyte death. Inflamm Bowel Dis 14(8):1027–1032. https://doi.org/10.1002/ibd.20433
Pallagi P, Balla Z, Singh AK, Dosa S, Ivanyi B, Kukor Z, Toth A, Riederer B, Liu Y, Engelhardt R, Jarmay K, Szabo A, Janovszky A, Perides G, Venglovecz V, Maleth J, Wittmann T, Takacs T, Gray MA, Gacser A, Hegyi P, Seidler U, Rakonczay Z Jr (2014) The role of pancreatic ductal secretion in protection against acute pancreatitis in mice*. Crit Care Med 42(3):e177–e188. https://doi.org/10.1097/CCM.0000000000000101
Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF (2003) 6-thioguanine–efficacy and safety in chronic active Crohn’s disease. Aliment Pharmacol Ther 17(4):503–508. https://doi.org/10.1046/j.1365-2036.2003.01440.x
Haber CJ, Meltzer SJ, Present DH, Korelitz BI (1986) Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 91(4):982–986. https://doi.org/10.1016/0016-5085(86)90703-1
Kirschner BS (1998) Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115(4):813–821. https://doi.org/10.1016/s0016-5085(98)70251-3
Venglovecz V, Rakonczay Z Jr, Ozsvari B, Takacs T, Lonovics J, Varro A, Gray MA, Argent BE, Hegyi P (2008) Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. Gut 57(8):1102–1112. https://doi.org/10.1136/gut.2007.134361
Moniz S, Sousa M, Moraes BJ, Mendes AI, Palma M, Barreto C, Fragata JI, Amaral MD, Matos P (2013) HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem Biol 8(2):432–442. https://doi.org/10.1021/cb300484r
Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher RC, Stutts MJ, Milgram SL (1998) An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem 273(31):19797–19801. https://doi.org/10.1074/jbc.273.31.19797
Moyer BD, Denton J, Karlson KH, Reynolds D, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M, Stanton BA (1999) A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J Clin Invest 104(10):1353–1361. https://doi.org/10.1172/JCI7453
Sun F, Hug MJ, Bradbury NA, Frizzell RA (2000) Protein kinase A associates with cystic fibrosis transmembrane conductance regulator via an interaction with ezrin. J Biol Chem 275(19):14360–14366. https://doi.org/10.1074/jbc.275.19.14360
Seinen ML, van Nieuw Amerongen GP, de Boer NK, van Bodegraven AA (2016) Rac attack: modulation of the small GTPase Rac in inflammatory bowel disease and thiopurine therapy. Mol Diagn Ther 20(6):551–557. https://doi.org/10.1007/s40291-016-0232-1
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D’Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC, Lee JC, Lees C, Lev-Tzion R, Lindsay JO, Mansfield J, Mawdsley J, Mazhar Z, Parkes M, Parnell K, Orchard TR, Radford-Smith G, Russell RK, Reffitt D, Satsangi J, Silverberg MS, Sturniolo GC, Tremelling M, Tsianos EV, van Heel DA, Walsh A, Watermeyer G, Weersma RK, Zeissig S, Rossjohn J, Holden AL, International Serious Adverse Events C, Group IBDPS, Ahmad T (2014) HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 46(10):1131–4. https://doi.org/10.1038/ng.3093
Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, van Haastert M, Ploeg RJ, Posthumus MD, van der Heide JJH, Jansen PL, van Dullemen HM (2004) Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther 20(8):843–850. https://doi.org/10.1111/j.1365-2036.2004.02197.x
Kerstein MD, Grabman J (1979) Amelioration of pancreatitis with azathioprine. Am J Gastroenterol 72(3):267–270
Satoh A, Gukovskaya AS, Reeve JR Jr, Shimosegawa T, Pandol SJ (2006) Ethanol sensitizes NF-kappaB activation in pancreatic acinar cells through effects on protein kinase C-epsilon. Am J Physiol Gastrointest Liver Physiol 291(3):G432–G438. https://doi.org/10.1152/ajpgi.00579.2005
Foitzik T, Forgacs B, Ryschich E, Hotz H, Gebhardt MM, Buhr HJ, Klar E (1998) Effect of different immunosuppressive agents on acute pancreatitis: a comparative study in an improved animal model. Transplantation 65(8):1030–1036. https://doi.org/10.1097/00007890-199804270-00004
Sanchez-Aldehuelo R, de Paredes AGG, Lazaro DR, Ortega AM, de la Filia Molina IG, Lopez-Duran S, Rodriguez-Gandia MA, Lopez-Sanroman A, Albillos A (2021) Outcomes of drug-induced acute pancreatitis: a ten-year experience of an academic center. Rev Esp Enferm Dig 113(4):276–279. https://doi.org/10.17235/reed.2020.7443/2020
Pallagi P, Venglovecz V, Rakonczay Z Jr, Borka K, Korompay A, Ozsvari B, Judak L, Sahin-Toth M, Geisz A, Schnur A, Maleth J, Takacs T, Gray MA, Argent BE, Mayerle J, Lerch MM, Wittmann T, Hegyi P (2011) Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl(-) channels and luminal anion exchangers. Gastroenterology 141(6):2228-2239e6. https://doi.org/10.1053/j.gastro.2011.08.039
Lee MG, Ohana E, Park HW, Yang D, Muallem S (2012) Molecular mechanism of pancreatic and salivary gland fluid and HCO3 secretion. Physiol Rev 92(1):39–74. https://doi.org/10.1152/physrev.00011.2011
Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-Toth M (2019) Genetics, cell biology, and pathophysiology of pancreatitis. Gastroenterology 156(7):1951-1968e1. https://doi.org/10.1053/j.gastro.2018.11.081
Angyal D, Bijvelds MJC, Bruno MJ, Peppelenbosch MP, de Jonge HR (2021) Bicarbonate transport in cystic fibrosis and pancreatitis. Cells. https://doi.org/10.3390/cells11010054
Dreiling DA, Nacchiero M (1978) The effect of Imuran on pancreatic secretion. A preliminary report. Am J Gastroenterol 69(4):491–493
Broe PJ, Cameron JL (1983) Azathioprine and acute pancreatitis: studies with an isolated perfused canine pancreas. J Surg Res 34(2):159–163. https://doi.org/10.1016/0022-4804(83)90055-0
Hegyi P, Wilschanski M, Muallem S, Lukacs GL, Sahin-Toth M, Uc A, Gray MA, Rakonczay Z Jr, Maleth J (2016) CFTR: a new horizon in the pathomechanism and treatment of pancreatitis. Rev Physiol Biochem Pharmacol 170:37–66. https://doi.org/10.1007/112_2015_5002
Madacsy T, Pallagi P, Maleth J (2018) Cystic fibrosis of the pancreas: the role of CFTR channel in the regulation of intracellular Ca(2+) signaling and mitochondrial function in the exocrine pancreas. Front Physiol 9:1585. https://doi.org/10.3389/fphys.2018.01585
Kunzelmann K, Mehta A (2013) CFTR: a hub for kinases and crosstalk of cAMP and Ca2+. FEBS J 280(18):4417–4429. https://doi.org/10.1111/febs.12457
Matos AM, Gomes-Duarte A, Faria M, Barros P, Jordan P, Amaral MD, Matos P (2018) Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR. Sci Rep 8(1):13026. https://doi.org/10.1038/s41598-018-31514-2
Iida T, Wagatsuma K, Hirayama D, Yokoyama Y, Nakase H (2019) The etiology of pancreatic manifestations in patients with inflammatory bowel disease. J Clin Med. https://doi.org/10.3390/jcm8070916
Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, Menchen L, Martin-Arranz MD, Opio V, Carneros JA, Van-Domselaar M, Mendoza JL, Luna M, Lopez P, Calvo M, Algaba A (2008) Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 28(5):623–628. https://doi.org/10.1111/j.1365-2036.2008.03746.x
Bangma A, Voskuil MD, Uniken Venema WTC, Brugge H, Hu S, Lanting P, Franke L, Dijkstra G, Festen EAM, Weersma RK (2020) Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Aliment Pharmacol Ther 51(11):1105–1115. https://doi.org/10.1111/apt.15762
Beekman JM (2016) Individualized medicine using intestinal responses to CFTR potentiators and correctors. Pediatr Pulmonol 51(S44):S23–S34. https://doi.org/10.1002/ppul.23553
Verkman AS, Galietta LJV (2021) Chloride transport modulators as drug candidates. Am J Physiol Cell Physiol 321(6):C932–C946. https://doi.org/10.1152/ajpcell.00334.2021
Funding
Open access funding provided by University of Szeged. The research was supported by the Momentum grant of the Hungarian Academy of Sciences (LP2017–18/2017 to JM) and Bolyai Research Fellowship (BO/00569/17 to PP) by funding from the Hungarian National Research, Development and Innovation Office (FK139269 to JM), by the National Excellence Programme (20391-3/2018/FEKUSTRAT and TKP2021-EGA-28 to JM, ÚNKP-19-3-I-SE-80 and EFOP 3.6.3-VEKOP-16-2017-00009 to BT, as well as UNKP-19-4-SZTE-21 and UNKP-18-4-SZTE-85 to PP). The project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593. This work was also supported by Albert Szent-Györgyi Research Grant (to MJ and PP) by the Faculty of Medicine, University of Szeged, and BT was supported by the scholarship of the National Talent Program (NTP-NFTÖ-20-B-0332).
Author information
Authors and Affiliations
Contributions
PP, JM, and BT designed the study. Animal handling, material preparation, data collection, and analysis were performed by BT, NP, AV, AK, MG, PS, TC, IHS, PH, MB, and NB. The first draft of the manuscript was written by BT, reviewed by JM and PP, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
All experiments were performed in line with the Hungarian regulations and EU directive 2010/63/EU for the protection of animals used for scientific purposes and the study was approved by the National Scientific Ethical Committee on Animal Experimentation (approval nr: CS/I01/2233-4/2018).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tél, B., Papp, N., Varga, Á. et al. Thiopurines impair the apical plasma membrane expression of CFTR in pancreatic ductal cells via RAC1 inhibition. Cell. Mol. Life Sci. 80, 31 (2023). https://doi.org/10.1007/s00018-022-04662-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00018-022-04662-y